US Edition
Enrolment concludes in Belite Bio’s trial of Tinlarebant for geographic atrophy
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Enrolment concludes in Belite Bio’s trial of Tinlarebant for geographic atrophy
Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant.The post Enrolment concludes in Belite Bio’s trial of Tinlarebant for geographic atrophy appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium